UBS Group AG Increases Holdings in ADMA Biologics Inc $ADMA

Key Points

• UBS Group AG increased its stake in ADMA Biologics by 129.9% in Q4 to 4,569,343 shares (about 1.92% of the company) valued at roughly $83.35 million.
• ADMA reported Q4 EPS of $0.20 (in line with estimates) and revenue of $139.16M (up 18.4% YoY), with strong margins (ROE 37.5%, net margin 28.8%); the stock has a market cap of $2.51B, a P/E of 17.5 and a 12‑month range of $7.21–$24.17.
• Analyst sentiment is mixed but the consensus is a "Moderate Buy" with a $25.67 target; concurrently, a director bought 7,000 shares while the COO sold 10,096, and institutional investors own about 75.7% of the stock (insiders ~3.9%).

UBS Group AG lifted its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 129.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,569,343 shares of the biotechnology company's stock after purchasing an additional 2,581,670 shares during the quarter. UBS Group AG owned about 1.92% of ADMA Biologics worth $83,345,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC raised its stake in shares of ADMA Biologics by 11.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company's stock worth $117,000 after purchasing an additional 634 shares during the last quarter. Cim LLC raised its stake in shares of ADMA Biologics by 0.7% in the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company's stock worth $1,341,000 after purchasing an additional 665 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 700 shares during the last quarter. Clearstead Advisors LLC raised its stake in shares of ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 795 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its stake in shares of ADMA Biologics by 1.7% in the third quarter. Oppenheimer & Co. Inc. now owns 49,230 shares of the biotechnology company's stock worth $722,000 after purchasing an additional 835 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $10.52 on Monday. The stock has a 50 day moving average of $12.50 and a 200 day moving average of $15.58. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The stock has a market cap of $2.51 billion, a P/E ratio of 17.53 and a beta of 0.83. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $24.17.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20. The company had revenue of $139.16 million during the quarter, compared to analysts' expectations of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.ADMA Biologics's quarterly revenue was up 18.4% on a year-over-year basis. During the same period last year, the business earned $0.46 earnings per share. As a group, sell-side analysts expect that ADMA Biologics Inc will post 0.93 EPS for the current year.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms purchased 7,000 shares of ADMA Biologics stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares of the company's stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on ADMA. Cantor Fitzgerald restated a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Wall Street Zen cut ADMA Biologics from a "buy" rating to a "hold" rating in a research note on Monday. Canaccord Genuity Group began coverage on ADMA Biologics in a research note on Monday, April 20th. They issued a "buy" rating and a $21.00 price objective for the company. Zacks Research cut ADMA Biologics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 27th. Finally, Mizuho reduced their price objective on ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating for the company in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, ADMA Biologics has an average rating of "Moderate Buy" and a consensus target price of $25.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.